Agency Information Collection Activities; Proposed eCollection, eComments Requested; Extension Without Change of a Previously Approved Collection; Application for Individual Manufacturing Quota for a Basic Class of Controlled Substance and for Ephedrine, Pseudoephedrine, and Phenylpropanolamine; DEA Form 189, 5722 [2019-03006]
Download as PDF
5722
Federal Register / Vol. 84, No. 36 / Friday, February 22, 2019 / Notices
AGENCY:
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information proposed to be collected
can be enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
permitting electronic submission of
responses.
The Department of Justice,
Drug Enforcement Administration
(DEA), is submitting the following
information collection request to the
Office of Management and Budget for
review and approval in accordance with
the Paperwork Reduction Act of 1995.
The proposed information collection
was previously published in the Federal
Register on December 14, 2018,
allowing for a 60 day comment period.
DATES: Comments are encouraged and
will be accepted for 30 days until March
25, 2019.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments,
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Kathy L. Federico, Diversion Control
Division, Drug Enforcement
Administration; Mailing Address: 8701
Morrissette Drive, Springfield, Virginia
22152; Telephone: (202) 598–6812.
Written comments and/or suggestions
can also be sent to the Office of
Management and Budget, Office of
Information and Regulatory Affairs,
Attention Department of Justice Desk
Officer, Washington, DC 20503, or sent
to OIRA_submission@omb.eop.gov.
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
Overview of This Information
Collection
1. Type of Information Collection:
Extension of a currently approved
collection.
2. Title of the Form/Collection:
Application for Individual
Manufacturing Quota for a Basic Class
of Controlled Substance and for
Ephedrine, Pseudoephedrine, and
Phenylpropanolamine.
3. The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
DEA Form 189. The applicable
component within the Department of
Justice is the Drug Enforcement
Administration, Diversion Control
Division.
4. Affected public who will be asked
or required to respond, as well as a brief
abstract:
Affected public (Primary): Business or
other for-profit.
Affected public (Other): None.
Abstract: Pursuant to 21 U.S.C. 826(c)
and 21 CFR 1303.22 and 1315.22, any
person who is registered to manufacture
any basic class of controlled substances
listed in Schedule I or II, or the List I
chemicals ephedrine, pseudoephedrine,
or phenylpropanolamine, and who
desires to manufacture a quantity of
such class or such List I chemical, must
apply on DEA Form 189 for a
manufacturing quota for such quantity
of such class or List I chemical.
5. An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: The DEA estimates 33
respondents complete 859 DEA Form
Square, 145 N Street NE, Suite 3E.405B,
Washington, DC 20530.
Dated: February 15, 2019.
Melody Braswell,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2019–03014 Filed 2–21–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
[OMB Number 1117–0006]
Agency Information Collection
Activities; Proposed eCollection,
eComments Requested; Extension
Without Change of a Previously
Approved Collection; Application for
Individual Manufacturing Quota for a
Basic Class of Controlled Substance
and for Ephedrine, Pseudoephedrine,
and Phenylpropanolamine; DEA Form
189
Drug Enforcement
Administration, Department of Justice.
ACTION: 30-Day notice.
SUMMARY:
VerDate Sep<11>2014
16:52 Feb 21, 2019
Jkt 247001
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
189 applications annually, and that each
form takes 0.5 hours to complete.
6. An estimate of the total public
burden (in hours) associated with the
proposed collection: The DEA estimates
this collection takes a total of 430
annual burden hours.
If additional information is required,
please contact: Melody Braswell,
Department Clearance Officer, United
States Department of Justice, Justice
Management Division, Policy and
Planning Staff, Two Constitution
Square, 145 N Street NE, Suite 3E.405B,
Washington, DC 20530.
Dated: February 15, 2019.
Melody Braswell,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2019–03006 Filed 2–21–19; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Office of Justice Programs
[OJP (OJP) Docket No. 1756]
Meeting of the Global Justice
Information Sharing Initiative Federal
Advisory Committee
Office of Justice Programs
(OJP), Justice.
ACTION: Notice of meeting.
AGENCY:
This is an announcement of a
meeting of the Global Justice
Information Sharing Initiative (Global)
Federal Advisory Committee (GAC) to
discuss the Global Initiative, as
described at www.it.ojp.gov/global. This
meeting will provide an update on
existing projects as well as a preview of
priorities for the FY19 Fiscal Year.
DATES: The meeting will take place on
Thursday, March 28, 2019, from 9:00
a.m. ET to 4:30 p.m. ET.
ADDRESSES: The meeting will take place
at the Office of Justice Programs offices
(in the Main Conference Room), 810 7th
Street, Washington, DC 20531; Phone:
(202) 514–2000 [note: this is not a tollfree number].
FOR FURTHER INFORMATION CONTACT:
Tracey Trautman, Global Designated
Federal Official (DFO), Bureau of Justice
Assistance, Office of Justice Programs,
810 7th Street, Washington, DC 20531;
Phone (202) 305–1491 [note: this is not
a toll-free number]; Email:
tracey.trautman@ojp.usdoj.gov.
SUPPLEMENTARY INFORMATION: This
meeting is open to the public. Due to
security measures, however, members of
the public who wish to attend this
meeting must register with Ms. Tracey
Trautman at the above address at least
SUMMARY:
E:\FR\FM\22FEN1.SGM
22FEN1
Agencies
[Federal Register Volume 84, Number 36 (Friday, February 22, 2019)]
[Notices]
[Page 5722]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-03006]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
[OMB Number 1117-0006]
Agency Information Collection Activities; Proposed eCollection,
eComments Requested; Extension Without Change of a Previously Approved
Collection; Application for Individual Manufacturing Quota for a Basic
Class of Controlled Substance and for Ephedrine, Pseudoephedrine, and
Phenylpropanolamine; DEA Form 189
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: 30-Day notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Justice, Drug Enforcement Administration
(DEA), is submitting the following information collection request to
the Office of Management and Budget for review and approval in
accordance with the Paperwork Reduction Act of 1995. The proposed
information collection was previously published in the Federal Register
on December 14, 2018, allowing for a 60 day comment period.
DATES: Comments are encouraged and will be accepted for 30 days until
March 25, 2019.
FOR FURTHER INFORMATION CONTACT: If you have additional comments,
especially on the estimated public burden or associated response time,
suggestions, or need a copy of the proposed information collection
instrument with instructions or additional information, please contact
Kathy L. Federico, Diversion Control Division, Drug Enforcement
Administration; Mailing Address: 8701 Morrissette Drive, Springfield,
Virginia 22152; Telephone: (202) 598-6812. Written comments and/or
suggestions can also be sent to the Office of Management and Budget,
Office of Information and Regulatory Affairs, Attention Department of
Justice Desk Officer, Washington, DC 20503, or sent to
OIRA_submission@omb.eop.gov.
SUPPLEMENTARY INFORMATION: Written comments and suggestions from the
public and affected agencies concerning the proposed collection of
information are encouraged. Your comments should address one or more of
the following four points:
--Evaluate whether the proposed collection of information is necessary
for the proper performance of the functions of the agency, including
whether the information will have practical utility;
--Evaluate the accuracy of the agency's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used;
--Evaluate whether and if so how the quality, utility, and clarity of
the information proposed to be collected can be enhanced; and
--Minimize the burden of the collection of information on those who are
to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submission of responses.
Overview of This Information Collection
1. Type of Information Collection: Extension of a currently
approved collection.
2. Title of the Form/Collection: Application for Individual
Manufacturing Quota for a Basic Class of Controlled Substance and for
Ephedrine, Pseudoephedrine, and Phenylpropanolamine.
3. The agency form number, if any, and the applicable component of
the Department sponsoring the collection: DEA Form 189. The applicable
component within the Department of Justice is the Drug Enforcement
Administration, Diversion Control Division.
4. Affected public who will be asked or required to respond, as
well as a brief abstract:
Affected public (Primary): Business or other for-profit.
Affected public (Other): None.
Abstract: Pursuant to 21 U.S.C. 826(c) and 21 CFR 1303.22 and
1315.22, any person who is registered to manufacture any basic class of
controlled substances listed in Schedule I or II, or the List I
chemicals ephedrine, pseudoephedrine, or phenylpropanolamine, and who
desires to manufacture a quantity of such class or such List I
chemical, must apply on DEA Form 189 for a manufacturing quota for such
quantity of such class or List I chemical.
5. An estimate of the total number of respondents and the amount of
time estimated for an average respondent to respond: The DEA estimates
33 respondents complete 859 DEA Form 189 applications annually, and
that each form takes 0.5 hours to complete.
6. An estimate of the total public burden (in hours) associated
with the proposed collection: The DEA estimates this collection takes a
total of 430 annual burden hours.
If additional information is required, please contact: Melody
Braswell, Department Clearance Officer, United States Department of
Justice, Justice Management Division, Policy and Planning Staff, Two
Constitution Square, 145 N Street NE, Suite 3E.405B, Washington, DC
20530.
Dated: February 15, 2019.
Melody Braswell,
Department Clearance Officer for PRA, U.S. Department of Justice.
[FR Doc. 2019-03006 Filed 2-21-19; 8:45 am]
BILLING CODE 4410-09-P